In partnership with international collaborators, Discovery Biology has contributed to the characterisation of a potent anti-malarial compound, ELQ-300. Recently published in Science: Translational Medicine, the pre-clinical compound is an inhibitor of mitochondrial cytochrome bc1 complex and has demonstrated efficacy in mouse models of malaria.
The Griffith University press release can be found here
The artcile can be found here
